Celldex Therapeutics, Inc. 8-K Filing
Ticker: CLDX · Form: 8-K · Filed: Nov 10, 2025 · CIK: 744218
| Field | Detail |
|---|---|
| Company | Celldex Therapeutics, Inc. (CLDX) |
| Form Type | 8-K |
| Filed Date | Nov 10, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Celldex Therapeutics, Inc. (ticker: CLDX) to the SEC on Nov 10, 2025.
How long is this filing?
Celldex Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 528 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-11-10 16:01:39
Filing Documents
- f8k_111025.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 76KB
- 0001171843-25-007179.txt ( ) — 294KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_111025_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 10, 2025, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter of 2025. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release of Celldex Therapeutics, Inc., dated November 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Celldex Therapeutics, Inc. Date: November 10, 2025 By: /s/ Sam Martin Sam Martin Senior Vice President and Chief Financial Officer